Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Regulation of Type I Interferon Signaling in Latently HIV-Infected CD4+ T lymphocytes
EF 2014-15
Résumé
Since their introduction almost thirty years ago, HIV-specific antiretroviral drugs have largely decreased AIDS related deaths. However, adverse side effects of these treatments have been described, including accelerated aging and neurological dysfunction stemming from long-term use. The inability to fully clear HIV from the patient is primarily due to a latent infection established within certain cells of the immune system. In these cells, no viral replication or protein expression occurs despite the HIV genome having been integrated into the cellular genetic material. These cells therefore act as a viral reservoir, in that they are resistant to antiviral drugs and may be a source of infectious virus should antiviral treatment be discontinued.
HIV infection itself is facilitated by a number of viral proteins, which in part impair antiviral signalling pathways within target cells. Although this impairment has been well studied during active infection, whether or not it is mirrored during latency is largely unknown. As such, this project primarily serves to identify if a deficient antiviral response exists within latently HIV-infected cells. In cancer research, similar impairment of antiviral mechanisms has been exploited to generate new therapies. A well characterized class of virus has been found to specifically target and kill cancer cells presenting these deficiencies. Thus, the ability of these cancer-killing oncolytic viruses to specifically target and destroy latently HIV-infected cells will form a second topic of study. In theory, this novel application of oncolytic viruses may serve as a means by which to specifically destroy the HIV reservoir while sparing healthy cells, thus achieving what current therapeutics cannot.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
331328
Name
Sandstrom Teslin S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Regulation of Type I Interferon Signaling in Latently HIV-Infected CD4+ T lymphocytes
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aids; Cd4+ T Lymphocyte; Hiv; Immunology; Interferon; Latency; Maraba; Oncolytic; Vesiculer Stomatitis Virus; Virology
Abstract
Since their introduction almost thirty years ago, HIV-specific antiretroviral drugs have largely decreased AIDS related deaths. However, adverse side effects of these treatments have been described, including accelerated aging and neurological dysfunction stemming from long-term use. The inability to fully clear HIV from the patient is primarily due to a latent infection established within certain cells of the immune system. In these cells, no viral replication or protein expression occurs despite the HIV genome having been integrated into the cellular genetic material. These cells therefore act as a viral reservoir, in that they are resistant to antiviral drugs and may be a source of infectious virus should antiviral treatment be discontinued.
HIV infection itself is facilitated by a number of viral proteins, which in part impair antiviral signalling pathways within target cells. Although this impairment has been well studied during active infection, whether or not it is mirrored during latency is largely unknown. As such, this project primarily serves to identify if a deficient antiviral response exists within latently HIV-infected cells. In cancer research, similar impairment of antiviral mechanisms has been exploited to generate new therapies. A well characterized class of virus has been found to specifically target and kill cancer cells presenting these deficiencies. Thus, the ability of these cancer-killing oncolytic viruses to specifically target and destroy latently HIV-infected cells will form a second topic of study. In theory, this novel application of oncolytic viruses may serve as a means by which to specifically destroy the HIV reservoir while sparing healthy cells, thus achieving what current therapeutics cannot.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sandstrom, Teslin S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~